Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer

Current Opinion in Urology

Volumn 23, Issue 5, 2013, Pages 429-434

  Gray, Phillip J ^a   Shipley, William U ^a   Efstathiou, Jason A ^a   Zietman, Anthony L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarkers; Chemoradiation; MRE11; Nonmuscle invasive bladder cancer

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN;

AGED; ALTERNATIVE MEDICINE; BLADDER CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CELL DAMAGE; CHEMORADIOTHERAPY; CYSTECTOMY; DNA DAMAGE; DNA REPAIR; FOLLOW UP; HUMAN; LONG TERM CARE; MUSCLE INVASIVE BLADDER CANCER; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION RESPONSE; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR RECURRENCE;

EID: 84881664232     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328363de04     Document Type: Review

References (47)

1. Soloway MS. ICUD-EAU International Consultation on Bladder Cancer 2012: Recommendations on bladder cancer-progress in a cancer that lacks the limelight. Eur Urol 2013; 63:1-3
2. Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013; 63:36-44
3. Manoharan M, Soloway MS. Optimal management of the T1G3 bladder cancer. Urol Clin North Am 2005; 32:133-145
4. Weiss C, Ott OJ, Wittlinger M, et al. Treatment options for high-risk T1 bladder cancer: Status quo and future perspectives of radiochemotherapy. Strahlenther Onkol 2008; 184:443-449
5. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983; 130:1083-1086
6. Yates DR, Brausi MA, Catto JW, et al. Treatment options available for bacillus Calmette-Guerin failure in nonmuscle-invasive bladder cancer. Eur Urol 2012; 62:1088-1096
7. National Comprehensive Cancer Network. Bladder Cancer. 2012; http:// www.nccn.org/professionals/physician-gls/pdf/bladder.pdf. [Accessed on 4 October 2013]
8. Bianco FJ Jr, Justa D, Grignon DJ, et al. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004; 22:290-294
9. Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995; 13:1404-1408
10. Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: Results from the National Cancer Data Base. Eur Urol 2013; 63:823-829
11. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: Evidence from the National Cancer Database, 2003 to 2007. J Urol 2011; 185:72-78
12. Logan C, Brown M, Hayne D. Intravesical therapies for bladder cancer: Indications and limitations. BJU Int 2012; 110 (Suppl 4):12-21
13. Nargund VH, Tanabalan CK, Kabir MN. Management of nonmuscle-invasive (superficial) bladder cancer. Semin Oncol 2012; 39:559-572
14. Gallagher BL, Joudi FN, Maymi JL, O'Donnell MA. Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology 2008; 71: 297-301
15. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006; 24:344-348
16. Di Lorenzo G, Perdona S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in nonmuscleinvasive bladder cancer: A multicenter prospective randomized trial. Cancer 2010; 116:1893-1900
17. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a Phase II prospective multicenter study. Urology 2005; 66:726-731
18. Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance. J Clin Oncol 2010; 28:543-548
19. Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 2009; 182: 1313-1317
20. Halachmi S, Moskovitz B, Maffezzini M, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol 2011; 29:259-264
21. Alfred Witjes J, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: Experience of the European Synergo working party. World J Urol 2009; 27:319-324
22. Gray PJ, Fedewa SA, Shipley WU, et al. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. J Clin Oncol 2013; 31:. (suppl 6; abstr 248
23. Canter D, Long C, Kutikov A, et al. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: Further evidence to support the use of neoadjuvant chemotherapy. BJU Int 2011; 107:58-62
24. Dutta SC, Smith JA Jr, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001; 166:490-493
25. McLaughlin S, Shephard J, Wallen E, et al. Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. Int Braz J Urol 2007; 33:25-31; discussion -2
26. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145:45-50
27. Ploeg M, Kiemeney LA, Smits GA, et al. Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol 2012; 30:247-251
28. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: Impact on prognosis after radical cystectomy. Eur Urol 2007; 51:137-149; discussion 49-51
29. Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: External validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011; 107:898-904
30. Quilty PM, Duncan W. Treatment of superficial (T1) tumours of the bladder by radical radiotherapy. Br J Urol 1986; 58:147-152
31. Gospodarowicz MK, Rider WD, Keen CW, et al. Bladder cancer: Long-Term follow-up results of patients treated with radical radiation. Clin Oncol (R Coll Radiol) 1991; 3:155-161
32. Harland SJ, Kynaston H, Grigor K, et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 2007; 178:807-813; discussion 13
33. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366:1477-1488
34. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:2901-2907
35. Weiss C, Wolze C, Engehausen DG, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006; 24:2318-2324
36. Wo JY, Shipley WU, Dahl DM, et al. The results of concurrent chemoradiotherapy for recurrence after treatment with bacillus Calmette-Guerin for nonmuscle-invasive bladder cancer: Is immediate cystectomy always necessary? BJU Int 2009; 104:179-183
37. Thomas F, Noon AP, Rubin N, et al. Comparative outcomes of primary, recurrent, and progressive high-risk nonmuscle-invasive bladder cancer. Eur Urol 2013; 63:145-154
38. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-Term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience. Eur Urol 2012; 61:705-711. [Epub ahead of print].
39. Mak R, Hunt D, Shipley W, et al. Long-Term outcomes in patients with muscleinvasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906 and 0233. J Clin Oncol 2012. (suppl 5; abstr 264
40. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-Term results. J Clin Oncol 2002; 20:3061-3071
41. Zapatero A, Martin De Vidales C, Arellano R, et al. Long-Term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: Neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology 2012; 80:1056-1062
42. Choudhury A, Swindell R, Logue JP, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 2011; 29:733-738
43. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J Clin Oncol 1993; 11:2150-2157
44. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladdersparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009; 27:4055-4061
45. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-Term survivors. J Urol 2003; 170:1772-1776
46. Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010; 70:7017-7026
47. Laurberg JR, Brems-Eskildsen AS, Nordentoft I, et al. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int 2012; 110:E1228-E1236